According to new research, the longer a person takes low-dose aspirin, the lower the risk of the development of his pancreatic cancer.
Professor of epidemiology, Harvey A. Risch, Yale school of public health says: "We found that the use of low-dose aspirin was associated with a reduction of pancreatic cancer in half, the data show that the longer was used aspirin in low doses, the lower the risk."
Low doses of the drug, which took men and women reduced the risk of cancer by 48 percent. Those who have been doing this for six years or less, the risk was decreased by 39%. Patients who took aspirin for 10 years showed a 60 percent decline. Low, for daily use, the dose of aspirin ranges from 75 to 325 mg.
The earlier a person started regularly taking low-dose aspirin, the greater the reduction in the risk of pancreatic cancer, he showed. Those who took it for three years before the start of the study showed a 48 percent reduction. Those who started taking it 20 years before the study was reduced by 60 %. On the other hand, discontinuation of aspirin within two years before the study was associated with a threefold increased risk of pancreatic cancer. Riche said: "This drug has some potential risks. Physicians should consider the advantages and disadvantages of aspirin for each individual based on personal characteristics and considerations."